The company's focus is to bring innovative medicines to patients with central nervous system disorders of high unmet medical need.
It is a subsidiary of Otsuka America Inc, a holding company established in the US in 1989.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze